TSHR fusion protein, and preparation method therefor and use thereof
By fusing the TSHR gene sequence with the lamprey variable lymphocyte receptor gene sequence, the TSHR fusion protein was constructed, which solved the problem of difficulty in expression of TSHR protein in E. coli and E.coli, and improved the stability and purity of the protein , quantitative detection of thyroid irritating antibodies has been achieved, laying the foundation for the diagnosis of thyroid disease.
Patent Information
- Application Number
- PCT/CN2023/132341
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-08
- Filing Date
- 2023-11-17
- Publication Date
- 2024-11-14
AI Technical Summary
The prior art is difficult to obtain soluble TSHR proteins in E. coli and E. coli, resulting in insufficient stability and purity of TSHR proteins in clinical practice, affecting the sensitivity and specificity of thyroid stimulating antibodies detection, and the recombinant protein expression is too small. Difficult to produce on a large scale.
By fusing the thyrotropin receptor (TSHR) gene sequence with the lamprey variable lymphocyte receptor (VLR) gene sequence, the modified TSHR fusion protein is constructed to improve its expression level and stability, and chemiluminescence reagents are used. Quantitative detection of thyroid-irritating antibodies was performed.
The expression and purity of TSHR protein were significantly improved, and effective distinction and quantitative detection of thyroid-stimulating antibodies were achieved, providing a theoretical basis for the diagnosis of thyroid disease and a basis for large-scale production.
Smart Images

Figure CN2023132341_14112024_PF_FP_ABST
Abstract
Description
A TSHR fusion protein and its preparation method and application
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Chinese patent application number CN202310507126.7, filed on May 8, 2023, the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present invention relates to the field of bioengineering technology, and in particular to a TSHR (thyroid stimulating hormone receptor) fusion protein and its preparation method and application. Specifically, the TSHR fusion protein is obtained by fusion expression of the TSHR gene sequence with the lamprey variable lymphocyte receptor (VLR) gene sequence. Background Art
[0004] The thyrotropin receptor (TSHR, https: / / www.uniprot.org / uniprotkb / P16473 / entry) is present on the membrane of thyroid follicular cells (TECs). It binds to thyroid-stimulating hormone (TSH) and regulates TEC growth, differentiation, synthesis, and release of thyroid hormones. Under the influence of environmental and genetic factors, the body's immune function becomes abnormal, and the TSHR becomes an autoantigen, producing autoantibodies (TRAb), leading to autoimmune thyroid disease (AITD). AITD is an organ-specific autoimmune disease that includes Graves' disease (GD), thyroiditis, and primary hypothyroidism. GD is the most common type of thyrotoxicosis, and TSHR is the most important pathogenic antigen in GD. TRAb is closely associated with the development of GD. TRAb is a heterogeneous polyclonal antibody, of which there are three main types: (1) thyroid stimulating antibodies (TSAb), which mainly stimulate the growth of thyroid follicles and increase the secretion of thyroid hormone by activating the adenylate cyclase-cyclic adenosine monophosphate (cAMP) pathway, leading to hyperthyroidism; TSAb is the main cause of GD and plays an important role in the occurrence and development of GD; (2) thyroid stimulating blocking antibodies (TSBAb), which can block the excitatory effect of TSH on the thyroid gland, causing hypothyroidism; (3) neutral autoantibodies, which neither activate TSHR nor block the activation of TSHR by TSH after binding to TSHR.
[0005] Numerous studies have shown that the epitope of thyroid-stimulating antibodies (TSAbs) primarily resides upstream of amino acid residue 289 in the TSHR. Therefore, recombining this protein segment is an effective means of detecting TSAbs in vivo. The TSHR is a G protein-coupled receptor, making in vitro recombinant expression and purification extremely difficult. Soluble TSHR protein is difficult to obtain in both Escherichia coli and E. coli. Therefore, the TSHR currently used in clinical practice is often derived from human or porcine thyroid cell membrane extracts or lysates expressing the full-length TSHR protein. Both methods suffer from protein stability and purity deficiencies, which can affect clinical sensitivity, specificity, and batch-to-batch variability. Ulrich et al. (see CN201580040213.X) in Germany fused the TSHR amino acid sequence with HSA and developed a kit using this as raw material, significantly improving stability and sensitivity. However, this approach suffers from the problem of low protein expression, making large-scale production unsuitable. Sanofi Pasteur studied the polymerization of recombinant proteins by fusing them to sequences from lamprey (CN107108755B), but did not address the following issues: improving the stability and purity of the target protein while increasing the expression level, nor did it involve the expression of TSHR fusion proteins.
[0006] Summary of the Invention
[0007] In order to overcome at least one problem existing in the prior art, the present invention significantly increases the expression level of TSHR by fusing the gene sequence of thyroid stimulating hormone receptor (TSHR) (TSHR agonist epitope gene sequence) with the receptor protein lamprey variable lymphocyte receptor (VLR).
[0008] To achieve the above object, the present invention adopts the following technical solutions:
[0009] The first aspect of the present invention is to provide a modified TSHR gene sequence, which comprises the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor.
[0010] Furthermore, the TSHR gene sequence comprises a partial gene sequence (including its full-length sequence) in the sequence shown in SEQ ID No. 1 (encoding amino acids 1-413 of the protein (full length 764aa)) or a nucleotide sequence having at least 85% homology with the partial gene sequence. The amino acid sequence encoded by the above partial gene sequence is capable of binding to thyroid stimulating antibodies (TSAb). The above TSHR amino acids 1-413 are the extracellular domain (ECD) of the TSHR receptor.
[0011] Furthermore, the TSHR gene sequence is one of the following sequences: the sequence shown in SEQ ID No. 2 (encoding protein amino acids 1-260) or a nucleotide sequence having at least 85% homology thereto, the sequence shown in SEQ ID No. 3 (encoding protein amino acids 1-289) or a nucleotide sequence having at least 85% homology thereto.
[0012] Furthermore, the gene sequence of the lamprey variable lymphocyte receptor includes the sequence shown in SEQ ID No. 4 or a nucleotide sequence having at least 85% homology thereto.
[0013] Furthermore, an exogenous sequence is inserted between the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor, and the exogenous sequence includes a nucleic acid sequence encoding a linker sequence and / or a protease cleavage site sequence.
[0014] It is understood that the above-mentioned linker can be a short peptide sequence or another suitable covalent connection between protein domains. Preferably, the linker is a short peptide sequence. Preferably, the peptide linker is composed of flexible residues such as glycine (G) and serine (S), so that adjacent protein domains are free to move relative to each other. Preferably, the linker is at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or at least 15 amino acid residues in length. It is understood that any possible linker can be used for the purpose of the present invention. For example, the linker can be a G6S9 (6 glycines followed by 9 serines) linker, a G8 linker, a G4S3 linker, a (GGGGS) 3-linker, a (EAAAK) 3-linker, etc.
[0015] It is understood that the above-mentioned protease cleavage site is a specific amino acid sequence that can be recognized by the protease. The above-mentioned cleavage site can be any suitable enzyme cleavage site conventionally used in the art, for example, it can be a Thrombin or TEV cleavage site.
[0016] The second aspect of the present invention is to provide a TSHR fusion protein, which is encoded by any modified TSHR gene sequence described in the first aspect of the present invention.
[0017] Furthermore, the TSHR fusion protein comprises the amino acid sequence of TSHR and the amino acid sequence of lamprey variable lymphocyte receptor, wherein the amino acid sequence of TSHR comprises a partial amino acid sequence (including the full-length sequence) in the sequence shown in SEQ ID No. 5 (1-413aa) or an amino acid sequence having at least 85% homology with the amino acid gene sequence. The above-mentioned partial amino acid sequence and its homologous sequence can bind to thyroid stimulating antibodies (TSAb). Specifically, the amino acid sequence of TSHR can be positions 1-260, 1-289, 1-413, 22-91, 246-260, 260-363, 380-413, 21-260, 21-413, 21-330, 261-330, etc. It is understood that other suitable TSHR epitopes that can bind to relevant antibodies or fragments thereof can be adopted.
[0018] Furthermore, an amino acid sequence having at least 85% homology to the amino acid sequence of TSHR is mutated based on its amino acid sequence. For example, in the sequence shown in SEQ ID No. 5 (1-413aa), the subsequent mutation sites include at least one of: R112P, D143P, D151E, V169R, and I253R. The purpose of the above amino acid site mutations is to further improve the stability and yield of protein expression.
[0019] Furthermore, the amino acid sequence of the TSHR is selected from one of the following sequences: an amino acid sequence (1-260aa) as shown in SEQ ID No.6 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb, an amino acid sequence (1-289aa) as shown in SEQ ID No.7 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb.
[0020] Furthermore, the amino acid sequence of the lamprey variable lymphocyte receptor includes the amino acid sequence shown in SEQ ID No. 8 or an amino acid sequence having at least 85% homology thereto.
[0021] Furthermore, the amino acid sequence having at least 85% homology to the amino acid sequence of the lamprey variable lymphocyte receptor is based on the amino acid sequence, with mutations at certain positions. Specifically, the amino acid sequence shown in SEQ ID No. 8 comprises amino acids 88-153 of the original amino acid sequence, with the following mutation at position 153: T153L. The aforementioned VLR fragments or mutations thereof are intended to increase protein expression by enhancing protein structural stability. Therefore, it is understood that VLR fragments and mutations thereof capable of achieving the aforementioned functions can be used to construct TSHR fusion proteins.
[0022] Furthermore, in a specific embodiment, the TSHR fusion protein is a TSHR1-289VLR fusion protein (consisting of the sequence shown in SEQ ID No.7 and the sequence shown in SEQ ID No.8) or a TSHR1-260VLR fusion protein (consisting of the sequence shown in SEQ ID No.6 and the sequence shown in SEQ ID No.8).
[0023] The specific sequences involved are shown in the following table:
[0024] Table 1 - Sequence information of TSHR
[0025] The third aspect of the present invention provides biological materials related to any of the modified TSHR gene sequences described in the first aspect of the present invention or any of the TSHR fusion proteins described in the first aspect of the present invention, which are recombinant vectors and recombinant cell lines containing the modified TSHR gene sequences. The recombinant vectors and recombinant cell lines are capable of expressing the TSHR fusion proteins.
[0026] Furthermore, the recombinant vector is a eukaryotic cell expression vector.
[0027] Furthermore, the eukaryotic cell expression vector includes a mammalian cell expression vector, and the mammalian cell expression vector includes a pCDNA3.1 plasmid and a pCMV plasmid.
[0028] Furthermore, the recombinant cell line is a eukaryotic cell.
[0029] Furthermore, the eukaryotic cells include mammalian cells, and the mammalian cells include HEK293 cells (such as Expi293 cells) and CHO cells.
[0030] It is understandable that the above-mentioned eukaryotic cell expression vectors and eukaryotic cells can be replaced by vectors and cells suitable for use in the art.
[0031] The fourth aspect of the present invention is to provide a chemiluminescent reagent for quantitative detection of TSAb, which includes TSHR fusion protein-streptavidin-coated magnetic particles, biotin and chemiluminescent substance-labeled thyroid-stimulating hormone receptor human monoclonal stimulating antibody M22, and the TSHR fusion protein is any TSHR fusion protein described in the second aspect of the present invention.
[0032] Furthermore, the TSHR fusion protein is a TSHR1-260 VLR fusion protein (composed of the sequence shown in SEQ ID No. 6 and the sequence shown in SEQ ID No. 8).
[0033] Furthermore, the chemiluminescent substance is preferably alkaline phosphatase (AP enzyme), and may also be other types of chemiluminescent substances suitably used in the art, such as ruthenium complexes, acridinium esters, and the like.
[0034] Furthermore, in the chemiluminescent reagent, the concentration of the TSHR fusion protein in the TSHR fusion protein-streptavidin-coated magnetic particles is 0.02-0.2 mg / mL (preferably 0.05-0.15 mg / mL, more preferably 0.1 mg / mL); the concentration of the streptavidin magnetic particles is 3-10 mg / mL (preferably 4-8 mg / mL, more preferably 5 mg / mL), and the particle size is 0.5-2 μm (preferably 0.8-1.5 μm, more preferably 1.2 μm); the concentration of the thyroid-stimulating hormone receptor human monoclonal stimulating antibody M22 labeled with biotin and chemiluminescent substances is 0.1-0.5 mg / mL (preferably 0.2-0.3 mg / mL, more preferably 0.25 mg / mL). In a specific embodiment, the concentration of the TSHR fusion protein-streptavidin-coated magnetic particles is 0.1 mg / mL, the concentration of the streptavidin magnetic particles is 5 mg / mL, and the particle size is 1.2 μm; the concentration of the thyroid-stimulating hormone receptor human monoclonal stimulating antibody M22 labeled with biotin and chemiluminescent substances is 0.25 mg / mL.
[0035] Furthermore, the preparation steps of the TSHR fusion protein-streptavidin-coated magnetic particles include: activation of magnetic beads; adding protein to the magnetic beads for magnetic bead cross-linking; blocking the magnetic beads; and washing and storing the magnetic beads.
[0036] Furthermore, the preparation steps of the biotin- and chemiluminescent-labeled thyroid-stimulating hormone receptor human monoclonal stimulating antibody M22 include: activation of the M22 antibody; taking alkaline phosphatase (AP enzyme), adding biotin, and activating the AP enzyme; mixing the activated AP with the activated M22 antibody to prepare the AP cross-linking antibody.
[0037] Furthermore, the implementation steps of the above-mentioned quantitative detection of TSAb are as follows: TSHR fusion protein-streptavidin-coated magnetic particles are added to the test sample for incubation; biotin and chemiluminescent substances are added to the thyroid-stimulating hormone receptor human monoclonal stimulating antibody M22, and the amount of TRAb bound to the labeled antibody M22 is determined by its ability to inhibit the binding of the labeled antibody M22 (for detecting TRAb mainly based on TSAb).
[0038] Furthermore, the sample includes serum, plasma, cell supernatant, etc.
[0039] It is understood that the above-mentioned chemiluminescent reagent for quantitative detection of TSAb is only used for illustration, and the TSHR fusion protein can also be prepared into any other suitable reagent for detecting TSAb or diagnosing thyroid disease.
[0040] The fifth aspect of the present invention is to provide an application of the modified TSHR gene sequence described in any of the first aspects of the present invention, or the TSHR fusion protein described in any of the second aspects of the present invention, the biomaterial described in any of the third aspects of the present invention, or the chemiluminescent reagent described in any of the fourth aspects of the present invention, which is selected from at least one of the following applications: application in the preparation of TSHR, application in detecting TSAb for non-diagnostic purposes (TSHR fusion protein as an antigen for detecting TSAb), application in the preparation of products for detecting TSAb, and application in the preparation of products for diagnosing thyroid disease.
[0041] Furthermore, the thyroid disease includes hyperthyroidism, thyrotoxicosis, Graves' disease, etc.
[0042] Furthermore, the method for detecting TSAb comprises the steps of: preparing the TSHR fusion protein into TSHR fusion protein-streptavidin-coated magnetic particles, adding a test sample (preferably a serum sample) for incubation; adding a human monoclonal stimulating antibody M22 labeled with biotin and a chemiluminescent substance to the thyroid stimulating hormone receptor, and determining the amount of TRAb bound to the labeled antibody M22 by its inhibitory ability to bind to the labeled antibody M22 (for detecting TRAb mainly based on TSAb); or, the method for detecting TSAb comprises the steps of: taking the TSHR fusion protein, diluting it into an ELISA plate, adding the test serum (i.e., the primary antibody) for incubation, adding a secondary antibody, the secondary antibody being an HRP-labeled anti-human IgG, and adding a colorimetric agent, thereby achieving the detection of TSAb. Specifically, the TSHR fusion protein is a TSHR1-260VLR fusion protein, wherein the TSHR amino acid sequence is shown in SEQ ID No. 6, and the VLR amino acid sequence is shown in SEQ ID No. 8. The above detections are all for obtaining corresponding intermediate detection results and are not based on diagnostic purposes.
[0043] Furthermore, the chemiluminescent substance is preferably alkaline phosphatase (AP enzyme), and may also be other types of chemiluminescent substances suitably used in the art, such as ruthenium complexes, acridinium esters, and the like.
[0044] Furthermore, the product for detecting TSAb is a chemiluminescent kit, which comprises the chemiluminescent reagent described in any one of the fourth aspects of the present invention, and further comprises a TSAb standard and a standard diluent (such as a commercially available Roche standard).
[0045] The sixth aspect of the present invention is to provide a method for preparing a TSHR fusion protein, which comprises the steps of: preparing the TSHR fusion protein by expressing any of the modified TSHR gene sequences described in the first aspect of the present invention, wherein the modified TSHR gene sequence comprises the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor.
[0046] Furthermore, in the above method for preparing TSHR fusion protein, the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor are constructed into a mammalian cell expression vector and transiently or stably transfected into eukaryotic cells.
[0047] Furthermore, the mammalian cell expression vector includes pCDNA3.1 plasmid, pCMV plasmid, and may also be other suitable vectors in the art, such as or with EF promoter and other eukaryotic expression vectors.
[0048] Furthermore, the eukaryotic cells include mammalian cells, and the mammalian cells include HEK293 cells (such as Expi293 cells) and CHO cells.
[0049] Furthermore, when constructing the gene sequence into a mammalian cell expression vector, a Kozac sequence is added before the start codon ATG, a His tag is added to the C-terminus, and an exogenous signal peptide is also added. The exogenous signal peptide can be a signal peptide commonly used in the art and can be tested by mammalian cell expression. In one embodiment, a signal peptide with good protein secretion expression effect of the TSHR fusion protein sequence is screened.
[0050] Furthermore, the above-mentioned method for preparing TSHR fusion protein also includes a purification step of the TSHR fusion protein, including: transient transfection of Expi293 cells in a shake flask, harvesting the secretion supernatant, hanging the column with a nickel-loaded IMAC pre-loaded column, washing and eluting with a buffer solution, dialyzing the eluted protein into a buffer solution, and concentrating it with a concentrator to obtain the purified TSHR fusion protein.
[0051] The seventh aspect of the present invention is to provide a method for diagnosing thyroid diseases (including hyperthyroidism, thyrotoxicosis, Graves' disease, etc.), which uses the modified TSHR gene sequence described in any of the first aspects of the present invention, or the TSHR fusion protein described in any of the second aspects of the present invention, the biomaterial described in any of the third aspects of the present invention, or the chemiluminescent reagent described in any of the fourth aspects of the present invention.
[0052] Compared with the prior art, the present invention adopts the above technical solution to achieve the following beneficial effects:
[0053] The present invention effectively ensures the stability and purity of the target protein and significantly improves its expression level by constructing a TSHR recombinant gene sequence, optimizing the expression system of its fusion protein and the protein purification method; at the same time, the present invention experimentally verifies that the TSHR fusion protein can effectively distinguish thyroid stimulating antibodies, and its ability to bind to thyroid stimulating antibodies can be measured by inhibiting the binding of the labeled antibody M22, thereby achieving quantitative detection of thyroid stimulating antibodies. The above provides a basis for the large-scale production of TSHR protein and a theoretical basis for the diagnosis of related thyroid diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of the present invention. The exemplary embodiments of the present invention and their descriptions are only used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:
[0055] FIG1 is a schematic diagram of the protein expression level of the fusion expression of the gene sequence of TSHR and lamprey variable lymphocyte receptor (TSHR1-260VLR) in one embodiment of the present invention;
[0056] FIG2 is a schematic diagram of the protein expression level of the fusion expression of the gene sequence of TSHR and lamprey variable lymphocyte receptor (TSHR1-289VLR) in one embodiment of the present invention;
[0057] FIG3 is a schematic diagram of protein expression levels using a fusion expression of the THSR sequence and human albumin gene in a comparative experiment of the present invention;
[0058] FIG4 is a schematic diagram showing the results of binding of TSHR1-260 VLR fusion protein to antibody M22 in one embodiment of the present invention;
[0059] FIG5 is a graph showing a standard curve of a standard substance in a chemiluminescent reagent according to an embodiment of the present invention;
[0060] FIG6 is a schematic diagram showing the correlation between the test concentration value and the Roche labeled value measured using a chemiluminescent reagent according to an embodiment of the present invention. DETAILED DESCRIPTION
[0061] The following will clearly and completely describe the technical solutions in the embodiments of the present invention in conjunction with the accompanying drawings. It is obvious that the described embodiments are only some of the embodiments of the present invention, and are not all of the embodiments. All other embodiments obtained by persons of ordinary skill in the art based on the embodiments of the present invention without inventive effort are within the scope of protection of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally measured in accordance with national standards. The experimental materials in the following examples, for which the sources are not specified, are all commercially available raw materials. The equipment used in each step of the following examples is conventional equipment. If there are no corresponding national standards, the steps are carried out in accordance with general international standards, conventional conditions, or conditions recommended by the manufacturer. Unless otherwise specified, all parts are by weight, and all percentages are by mass percentages. Unless otherwise defined or specified, all professional and scientific terms used in the present invention have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention.
[0062] In one embodiment of the present invention, the modified TSHR gene sequence includes the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor, wherein the gene sequence of TSHR includes the partial gene sequence (including its full-length sequence) of the sequence shown in SEQ ID No. 1 (encoding amino acids 1-413 of the protein (full length 764aa)) or a nucleotide sequence having at least 85% homology with the partial gene sequence, and the gene sequence of lamprey variable lymphocyte receptor includes SEQ ID No. 4 or a nucleotide sequence having at least 85% homology thereto. The amino acid sequence encoded by the above partial gene sequence is capable of binding to thyroid stimulating antibodies (TSAb). The TSHR fusion protein comprises the amino acid sequence of TSHR and the amino acid sequence of lamprey variable lymphocyte receptor, wherein the amino acid sequence of TSHR is a partial amino acid sequence (including the full-length sequence) of the sequence shown in SEQ ID No. 5 (1-413aa) or an amino acid sequence having at least 85% homology with the amino acid gene sequence, and the amino acid sequence of lamprey variable lymphocyte receptor comprises SEQ ID No. 8 or an amino acid sequence having at least 85% homology thereto. The above homology can be specifically 85%, 90%, 95%, etc.
[0063] The term "homology" refers to the number of exactly matched nucleotides / amino acids between two sequences aligned in a sequence alignment (expressed as a percentage), which is calculated using the number of identical positions divided by the number of equivalent positions in the larger sequence or excluding overhangs in the shortest sequence, wherein internal gaps are counted as equivalent positions; in certain embodiments, any reference to sequence homology expressed herein may be replaced by sequence similarity or sequence identity. The term "mutation" refers to the replacement of one amino acid or nucleotide by another amino acid or nucleotide, and the mutation also includes mutations obtained by known synthetic techniques, for example, mutations obtained by using traditional peptide synthesis to affect the synthesis of a desired polypeptide sequence, wherein the synthesized sequence includes the replacement of a desired amino acid with another amino acid.
[0064] It should be noted that, in the absence of conflict, the embodiments and features of the embodiments of the present invention can be combined with each other. The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but they are not intended to limit the present invention.
[0065] The experimental materials used in the following examples include:
[0066] Expression cells: Expi293 Thermo Fisher Scientific;
[0067] Culture medium: Optima CD05;
[0068] Nickel-loaded IMAC resin: Jinsirui Biotechnology;
[0069] Protein A280 concentration determination Nanodrop: Aosheng Nano-300;
[0070] Imidazole, phosphate, Tris-base, NaCl and other chemical reagents: Shanghai Bioengineering;
[0071] SDS-page gel electrophoresis system: Tanon Shanghai Tianneng Technology Co., Ltd.
[0072] Example 1 - Preparation of TSHR-VLR fusion protein and protein expression detection
[0073] In this example, two TSHR-VLR fusion proteins were prepared: TSHR1-260 VLR fusion protein (TSHR gene sequence is shown in SEQ ID No. 2, VLR gene sequence is shown in SEQ ID No. 4; TSHR amino acid sequence is shown in SEQ ID No. 6, VLR amino acid sequence is shown in SEQ ID No. 8) and TSHR1-289 VLR fusion protein (TSHR gene sequence is shown in SEQ ID No. 3, VLR gene sequence is shown in SEQ ID No. 4; TSHR amino acid sequence is shown in SEQ ID No. 7, VLR amino acid sequence is shown in SEQ ID No. 8).
[0074] (1) Synthesis of fusion protein gene sequence
[0075] The gene sequences of the above-mentioned TSHR1-260VLR fusion protein and TSHR1-289VLR fusion protein were both synthesized by Universal Biosystems (Anhui) Co., Ltd. During the synthesis process, a Kozac sequence was added before the start codon ATG, and a His tag was added to the C-terminus to construct them into the pCDNA3.1 mammalian cell expression vector (other expression vectors such as pCMV can also be selected as an alternative), and the sequencing was correct.
[0076] Signal peptides with good secretion and expression effects on TSHR sequence fusion protein 1 and TSHR fusion protein sequence 2 proteins can be screened out through mammalian cell expression detection, such as GAUSSIA LUCIFERASE SP: MGVKVLFALICIAVAEA (ATGGGAGTCAAAGTTCTGTTTGCCCTGATCTGCATCGCTGT GGCCGAGGCC); murine IgG kappa V SP: MDMRVPAQLLGLLLLWFSGVLG (ATGGATATGAGAGTTCCTGCTCAATTGCTGGGGTTGCTCTTGCTCTGGTTCAGTGGGGTGTTGGGG), but the exogenous signal peptides are not limited to the preferred signal peptides disclosed in this example.
[0077] (2) Transient transfection of mammalian cells Expi293 and protein expression detection
[0078] Expi 293 transient transfection method: Follow the protocol provided by Opma. Expi 293 cells are cultured in 293 medium. After reaching a density of 1 x 10⁶, a mixture of PEI and plasmid is added. The cell-to-plasmid ratio is typically 1 μg of plasmid per ml of cells, with a PEI-to-plasmid ratio of 3:1. After mixing, the cells are incubated in a shaker at 37°C. 293pro FEED is typically added on the second and fifth days. On the seventh day, the cell supernatant is harvested by centrifugation for protein purification and identification. The protein purification steps included: transient transfection of Expi293 cells in a shake flask, harvesting 1 L of secretion supernatant, and loading onto a 5 ml column volume of nickel-loaded IMAC prepacked column equilibrated with 20 mM PB, 500 mM NaCl, pH 7.4; washing for 5 column volumes with 20 mM PB, 500 mM NaCl, 20 mM imidazole, pH 7.4 buffer, and washing for 5 column volumes with 20 mM PB, 500 mM NaCl, 50 mM imidazole, pH 7.4 buffer. Elution was then performed with 20 mM PB, 500 mM NaCl, 500 mM imidazole, pH 7.4 buffer. The eluted protein was dialyzed into PBS, pH 7.4 buffer, and concentrated using a 3 kDa cutoff concentrator. The resulting TSHR1-289 VLR fusion protein and the expression results of the TSHR1-289 VLR fusion protein are shown in Figures 1 and 2, respectively.
[0079] The above results show that the expression level of TSHR1-260VLR fusion protein in 293 cells is about 5 mg / L, and the expression level of TSHR1-289VLR is about 3 mg / L.
[0080] (3) Steady-state transfection of mammalian CHO cells and protein expression detection
[0081] CHO stable transfection method: The gene is transferred into CHO cells, and the cells are screened using the corresponding screening marker antibiotics (such as puromycin) or GS auxotrophic marker screening method. The stable cells obtained become CHO stable cell lines. The results show that the current expression levels of TSHR1-260VLR fusion protein and TSHR1-289VLR fusion protein in CHO stable transfection cells are approximately 10-fold higher than transient expression. Specifically, the protein expression level is approximately 25 mg / L under non-feed conditions, and can be further increased by 10-20 times (approximately several hundred milligrams) under feed conditions.
[0082] The establishment of the above-mentioned CHO stable expression strain further improved the protein expression level, which provided a basis for subsequent large-scale production.
[0083] (4) Comparative experimental group - TSHR1-260HSA fusion protein expression
[0084] The control experimental group used the THSR1-260 sequence and the human albumin gene for fusion expression. The gene sequence and amino acid sequence are shown in Table 1 above. The protein transient expression steps were the same as the above step (2). The results showed that the protein expression level was very low, 100 micrograms per liter, which was not suitable for large-scale production. Figure 3 is a schematic diagram of the supernatant expression detected by His antibody.
[0085] From the above comparison, it can be seen that the TSHR protein expression levels obtained by the transient and stable expression systems of TSHR-VLR fusion protein constructed in this example are much higher than those in the expression systems in the prior art.
[0086] Example 2 - Application of TSHR-VLR fusion protein in detecting thyroid stimulating antibodies (TSAb)
[0087] The application of the prepared TSHR1-260 VLR fusion protein in detecting thyroid stimulating antibodies (TSAb) in this embodiment includes the following steps:
[0088] The TSHR1-260 VLR fusion protein was diluted to 1 μg / mL with PBS and added to the ELISA plate at 100 ng / well. The plate was coated overnight and blocked with 5% skim milk the next day. The positive patient serum was from 26 positive cases of hyperthyroidism, and the negative control was normal human serum. The plate was diluted 1:10,000 and 100 μL was added to each well. The plate was incubated at 37°C for 1 hour. After thorough washing with PBST, the secondary antibody, HRP-labeled anti-human IgG, was added. The plate was incubated at 37°C for 1 hour. After thorough washing with PBST, the colorimetric reagent was added. The results are shown in the following table:
[0089] The above results show that the TSHR1-260VLR fusion protein has a strong discrimination in detecting thyroid stimulating antibodies, which indicates that the TSHR-VLR fusion protein can be used as an antigen for detecting thyroid stimulating antibodies.
[0090] Example 3-TSHR1-260 VLR fusion protein and antibody M22 binding experiment
[0091] This example validates the binding of the TSHR1-260 VLR fusion protein to the thyroid stimulating hormone receptor human monoclonal stimulatory antibody M22. The method comprises the following steps: coating 100 ng of antibody M22 (RSR) onto an ELISA plate, incubating with TSHR1-260 VLR protein at a starting concentration of 1 μg / mL and a 3-fold dilution, performing eight gradients, then adding an HRP-labeled anti-His antibody (GenScript A00612), and finally developing with an HRP substrate (Biyuntian P0209). The results are shown in the following table and Figure 4.
[0092] Based on the above data, the binding EC50 of TSHR1-260 VLR fusion protein and antibody M22 was calculated to be 7 ng / mL.
[0093] Example 4 - Application of TSHR1-260 VLR fusion protein in chemiluminescent reagents
[0094] This example verifies the use of the TSHR1-260 VLR fusion protein in a chemiluminescent reagent. The preparation method of the chemiluminescent reagent comprises the following steps:
[0095] 1) Preparation of TSHR fusion protein-streptavidin-coated magnetic particles (magnetic beads);
[0096] Magnetic bead activation: Take magnetic beads, add NHS and EDC, mix thoroughly, and dilute to 0.5 mg / mL with MES buffer; Magnetic bead cross-linking protein: Add TSHR1-260VLR fusion protein to the magnetic beads under stirring; Magnetic bead blocking: Add magnetic bead blocking solution, react on a mixer at room temperature for 24 hours, and dilute with diluent to a magnetic bead concentration of approximately 10 mg / mL; Magnetic bead cleaning and storage: Magnetic separation, discard the supernatant; resuspend with washing solution, mix on a mixer for 5 minutes; magnetic separation for 5 minutes, discard the supernatant; add preservation solution, mix on a mixer for 30 minutes; the final concentration is 5.0 mg / mL (0.5%), and store at +2 to +8°C.
[0097] In the TSHR fusion protein-streptavidin-coated magnetic particles prepared above, the concentration of TSHR fusion protein was 0.1 mg / mL, the final concentration of streptavidin magnetic particles was 5 mg / mL, and the particle size was 1.2 μm.
[0098] 2) Preparation of human monoclonal stimulatory antibody M22 against thyrotropin receptor labeled with biotin and chemiluminescent substances;
[0099] Antibody Activation: Add TCEP-HCl 7.0 solution to the antibody and mix thoroughly. Add TCEP solution to the antibody solution, mix rapidly, and react for 2 hours. Alkaline Phosphatase (AP) Activation: Add biotin to AP, mix thoroughly, and incubate at room temperature (+25°C) for 60 minutes. AP Cross-linking Antibody: Add activated AP to the activated antibody, mix thoroughly, incubate at room temperature (+25°C) for 4 hours, and then add diluent to a concentration of 0.25 mg / mL.
[0100] The final concentration of the biotin- and chemiluminescent-labeled thyroid stimulating hormone receptor human monoclonal stimulating antibody M22 is 0.25 mg / mL.
[0101] The detection of the above-mentioned chemiluminescent reagent includes the steps of: coating magnetic particles with TSHR fusion protein-streptavidin, adding the test sample for incubation, and then adding biotin and chemiluminescent substance-labeled thyroid stimulating hormone receptor human monoclonal stimulating antibody M22, and determining its binding ability by inhibiting the binding of the labeled antibody M22 to determine the amount of TRAb (TRAb mainly composed of TSAb). Specifically, the concentration of TSAb in the sample to be tested is calculated through a standard curve. In the above-mentioned detection steps, the amount of TSHR fusion protein-streptavidin-coated magnetic particles, the amount of biotin and ruthenium complex-labeled thyroid stimulating hormone receptor human monoclonal stimulating antibody M22, and the amount of test sample can all be determined by referring to conventional methods in the field. Other auxiliary reagents used in the detection process can also refer to conventional methods in the field.
[0102] Standard curve construction: Using Roche standards (TSAb standards), perform the assay according to the assay protocol for the sample to be tested, read the RLU values, and fit the standard curve to determine sample concentration. The results are shown in the table below and Figure 5.
[0103] From the above table data and FIG5 , it can be seen that in this embodiment, the standard sample with different dilution concentrations was tested, and its standard curve was a four-parameter logistic curve fit, and the equation was y=(AD) / [1+(x / C)^B]+D; wherein: A=731015.08198; B=1.38702; C=5.08890; D=11265.48915; R 2 =0.99961.
[0104] This example also verifies the correlation between the test concentration value and the Roche labeled value measured by the above chemiluminescent reagent, and the results are shown in the following table and Figure 6:
[0105] From the above table data and Figure 6, it can be seen that in this embodiment, different concentrations of test samples are used, and the concentration values of the test samples and the Roche labeled values are linearly analyzed by the measured RLU values to calculate the linear correlation coefficient. The result is: y = 0.9724x - 0.0328, R 2 =0.9716. The above results indicate that the chemiluminescent reagent prepared using the TSHR1-260 VLR fusion protein in this example can achieve quantitative detection of TRAb.
[0106] As can be seen from the above examples, the present invention screened and obtained a VLR sequence for the first time, which can be used to construct a stably expressed TSHR-VLR fusion protein with a TSHR sequence. The method adopted by the present invention can prepare a TSHR fusion protein with high protein expression and high purity, which can effectively distinguish thyroid stimulating antibodies. Its ability to bind to thyroid stimulating antibodies can be measured by its ability to inhibit the binding of the labeled antibody M22, thereby realizing the quantitative detection of thyroid stimulating antibodies, which lays a certain foundation for the large-scale production of TSHR protein and the diagnosis of thyroid disease.
[0107] While the specific embodiments of the present invention have been described in detail above, these are intended to be exemplary only, and the present invention is not limited thereto. For those skilled in the art, any equivalent modifications and substitutions to the present invention are also within the scope of the present invention. Therefore, any equivalent changes and modifications made without departing from the spirit and scope of the present invention are intended to be encompassed within the scope of the present invention.
Claims
1. A modified TSHR gene sequence, characterized in that: The modified TSHR gene sequence comprises the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor.
2. A modified TSHR gene sequence according to claim 1, characterized in that: The TSHR gene sequence comprises one of the following sequences: a sequence as shown in SEQ ID No.1 or a nucleotide sequence having at least 85% homology thereto, a sequence as shown in SEQ ID No.2 or a nucleotide sequence having at least 85% homology thereto, a sequence as shown in SEQ ID No.3 or a nucleotide sequence having at least 85% homology thereto; And / or, the gene sequence of the lamprey variable lymphocyte receptor includes the sequence shown in SEQ ID No. 4 or a nucleotide sequence having at least 85% homology thereto.
3. A modified TSHR gene sequence according to claim 1, characterized in that: An exogenous sequence is inserted between the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor, and the exogenous sequence includes a nucleic acid sequence encoding a linker sequence and / or a protease cleavage site sequence.
4. A TSHR fusion protein, characterized in that The amino acid sequence of the TSHR fusion protein is encoded by the modified TSHR gene sequence according to any one of claims 1 to 3.
5. A TSHR fusion protein according to claim 4, characterized in that: The TSHR fusion protein comprises an amino acid sequence of TSHR and an amino acid sequence of lamprey variable lymphocyte receptor, wherein the amino acid sequence of TSHR comprises one of the following sequences: an amino acid sequence as shown in SEQ ID No.5 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb, an amino acid sequence as shown in SEQ ID No.6 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb, an amino acid sequence as shown in SEQ ID No.7 or an amino acid sequence having at least 85% homology thereto and the amino acid sequence binds to TSAb; And / or, the amino acid sequence of the lamprey variable lymphocyte receptor comprises the amino acid sequence shown in SEQ ID No. 8 or an amino acid sequence having at least 85% homology thereto.
6. A biological material related to the modified TSHR gene sequence according to any one of claims 1 to 3 or to the TSHR fusion protein sequence according to any one of claims 4 to 5, characterized in that: The biological material comprises a recombinant vector and a recombinant cell line containing the modified TSHR gene sequence according to any one of claims 1 to 3.
7. The biomaterial according to claim 6, characterized in that The recombinant vector is a eukaryotic cell expression vector, which includes a mammalian cell expression vector, and the mammalian cell expression vector includes a pCDNA3.1 plasmid and a pCMV plasmid; And / or, the recombinant cell line is a eukaryotic cell, the eukaryotic cell includes a mammalian cell, and the mammalian cell includes a HEK293 cell and a CHO cell.
8. A chemiluminescent reagent for quantitative detection of TSAb, characterized in that: The chemiluminescent reagent comprises TSHR fusion protein-streptavidin coated magnetic particles, biotin and chemiluminescent substance labeled thyroid stimulating hormone receptor human monoclonal stimulating antibody M22, and the TSHR fusion protein is the TSHR fusion protein described in any one of claims 4-5.
9. The chemiluminescent reagent according to claim 8, characterized in that In the TSHR fusion protein-streptavidin coated magnetic particles, the concentration of TSHR fusion protein is 0.02-0.2 mg / mL, the concentration of streptavidin magnetic particles is 3-10 mg / mL, and the particle size of streptavidin magnetic particles is 0.5-2 μm; the concentration of the thyroid stimulating hormone receptor human monoclonal stimulating antibody M22 labeled with biotin and chemiluminescent substances is 0.1-0.5 mg / mL.
10. A use of the modified TSHR gene sequence according to any one of claims 1 to 3, the TSHR fusion protein according to any one of claims 4 to 5, the biomaterial according to any one of claims 6 to 7, or the chemiluminescent reagent according to any one of claims 8 to 9, characterized in that: The application is selected from at least one of the following applications: application in the preparation of TSHR, application in the detection of TSAb for non-diagnostic purposes, application in the preparation of products for detecting TSAb, and application in the preparation of products for diagnosing thyroid disease.
11. A method for preparing a TSHR fusion protein, characterized in that: The method comprises the steps of: preparing the TSHR fusion protein by expressing the modified TSHR gene sequence according to any one of claims 1 to 3, wherein the modified TSHR gene sequence comprises the gene sequence of TSHR and the gene sequence of lamprey variable lymphocyte receptor.
12. The method for preparing TSHR fusion protein according to claim 11, characterized in that: The gene sequence of the TSHR and the gene sequence of the lamprey variable lymphocyte receptor are constructed into a mammalian cell expression vector and transiently or stably transfected into eukaryotic cells.
Citation Information
Patent Citations
Multimerization of recombinant protein by fusion to a sequence from lamprey
CN107108755A
Human thyroid stimulating hormone receptor fusion protein as well as preparation method and application thereof
CN111548422A
Recombinant thyroid stimulating hormone receptor protein, preparation method and application
CN115925966A
Water-Soluble Polypeptides Comprised of Repeat Modules, Method for Preparing the Same and Method for a Target-Specific Polypeptide and Analysis of Biological Activity Thereof
US20140088292A1
